MOH — authorised 29 January 2013
- Marketing authorisation holder: GENZYME CORP
- Status: likely_approved
MOH authorised Kynamro on 29 January 2013
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 29 January 2013.
GENZYME CORP holds the Israeli marketing authorisation.